Top

Published in:

01-11-2018 | Original Communication

Risk factors of suicidal ideation in Huntington’s disease: literature review and data from Enroll-HD

Authors: Philipp Honrath, Imis Dogan, Olga Wudarczyk, Katharina S. Görlich, Mikhail Votinov, Cornelius J. Werner, Beate Schumann, Rena T. Overbeck, Jörg B. Schulz, Bernhard G. Landwehrmeyer, Raquel E. Gur, Ute Habel, Kathrin Reetz, the Enroll-HD investigators

Published in: Journal of Neurology | Issue 11/2018

Abstract

Suicide is a leading cause of death in Huntington’s disease (HD), following pneumonia. Up to one-fifth of individuals with HD report suicidal ideation. Identifying the risk factors of suicidal ideation in this clinical population is thus pivotal. Here, we review the literature on prevalence rates and risk factors of suicidal ideation in premanifest and manifest patients and re-evaluate them using the largest currently existing clinical dataset from the ongoing observational study “Enroll-HD” (N = 5709). Large scale studies yielded important insights regarding suicidal ideation in HD. However, estimated prevalence rates vary among studies and risk factors are still poorly understood. According to the Enroll-HD data, pre- and manifest disease stages are associated with current (5.8–10%) and a history of suicidal ideation (18.6–30.9%). Throughout the course of HD, a history of suicidal ideation and the presence of depressive symptoms were strongly associated with current suicidal ideation. However, while for premanifest individuals, socio-demographics and activities of daily living appear to be important, in manifest patients, suicidal ideation is more closely linked to anxiety, irritability, psychosis, and apathy. These results highlight the importance of treating depressive symptoms in patients with HD and addressing potential suicidal ideation during clinical monitoring. The relevance of risk factors may differ among premanifest and manifest patients.

WHO (2016) Suicide rates (per 100000 population). http://www.who.int/gho/mental_health/suicide_rates/en/. Accessed 27 Sept 2017

Nock MK, Borges G, Bromet EJ et al (2008) Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry 192(2):98–105CrossRef

Bolton JM, Gunnell D, Turecki G (2015) Suicide risk assessment and intervention in people with mental illness. BMJ 351:h4978-hCrossRef

Qin P, Nordentoft M, Hoyer EH, Agerbo E, Laursen TM, Mortensen PB (2006) Trends in suicide risk associated with hospitalized psychiatric illness: a case-control study based on Danish longitudinal registers. J Clin Psychiatry 67(12):1936–1941CrossRef

Hesdorffer DC (2016) Comorbidity between neurological illness and psychiatric disorders. CNS spectrums 21(3):230–238CrossRef

Arciniegas DB, Anderson CA (2002) Suicide in neurologic illness. Curr Treatment Options Neurol 4(6):457–468CrossRef

Huntington G (1872) On chorea. Med Surg Rep Weekly J 26(15):317–21

Rodrigues FB, Abreu D, Damásio J et al (2017) Survival, mortality, causes and places of death in a European Huntington’s disease prospective cohort. Movement Disorders Clinical Practice.

Paulsen JS, Nehl C, Hoth KF et al (2005) Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci 17(4):496–502CrossRef

10.

Baliko L, Csala B, Czopf J (2004) Suicide in Hungarian Huntington’s disease patients. Neuroepidemiology 23(5):258–260. https://doi.org/10.1159/000079953 CrossRefPubMed

11.

Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM (1993) Suicide risk in Huntington’s disease. J Med Genet 30(4):293–295CrossRef

12.

Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 27(9):1083–1091. https://doi.org/10.1002/mds.25075 CrossRefPubMed

13.

Nance M, Paulsen JS, Rosenblatt A, Wheelock V (2011) A physician’s guide to the management of Huntington’s disease. Huntington’s Disease Society of America, New York

14.

van Duijn E, Kingma E, van der Mast R (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19(4):441–448CrossRef

15.

Epping EA, Paulsen JS (2011) Depression in the early stages of Huntington disease. Neurodegener Dis Manag 5(1):407–414CrossRef

16.

Orth M (2011) Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY. J Neurol Neurosurg Psychiatry 82(12):1409–1412CrossRef

17.

Dorsey ER, Investigators HSGC (2012) Characterization of a large group of individuals with Huntington disease and their relatives enrolled in the COHORT study. PloS one 7(2):e29522CrossRef

18.

Kieburtz K, Penney JB, Corno P et al (2001) Unified Huntington’s disease rating scale: reliability and consistency. Neurology 11(2):136–142

19.

Langbehn DR, Hayden MR, Paulsen JS (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet Part B Neuropsychiatr Genet 153(2):397–408CrossRef

20.

Craufurd D, Thompson JC, Snowden JS (2001) Behavioral changes in Huntington disease. Cogn Behav Neurol 14(4):219–226

21.

Penney JB, Vonsattel JP, Macdonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41(5):689–692CrossRef

22.

Beck AT, Steer RA, Brown GK (1996) Beck depression inventory-II. San Antonio 78(2):490–498

23.

Posner K, Brent D, Lucas C et al (2008) Columbia-suicide severity rating scale (C-SSRS). Columbia University Medical Center, New York

24.

van Duijn E, Vrijmoeth EM, Giltay EJ, Landwehrmeyer GB, Network RiotEHsD (2017) Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington’s disease gene expansion carriers. J Affect Disord 228:194–204CrossRef

25.

Paulsen JS, Hoth KF, Nehl C, Stierman L (2005) Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry 162(4):725–731CrossRef

26.

Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC (2012) Suicidality in Huntington’s disease. J Affect Disord 136(3):550–557. https://doi.org/10.1016/j.jad.2011.10.031 CrossRefPubMed

27.

Anderson KE, Eberly S, Groves M et al (2016) Risk factors for suicidal ideation in people at risk for Huntington’s disease. J Huntingt Dis 5(4):389–394CrossRef

28.

Wetzel HH, Gehl CR, Dellefave-Castillo L, Schiffman JF, Shannon KM, Paulsen JS (2011) Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res 188(3):372–376. https://doi.org/10.1016/j.psychres.2011.05.006 CrossRefPubMedPubMedCentral

29.

Hubers AA, van Duijn E, Roos RA et al (2013) Suicidal ideation in a European Huntington’s disease population. J Affect Disord 151(1):248–258. https://doi.org/10.1016/j.jad.2013.06.001 CrossRefPubMed

30.

Coustasse A, Pekar A, Sikula A, Lurie S (2009) Ethical considerations of genetic presymptomatic testing for Huntington’s disease. J Hosp Market Pub Relat 19(2):129–141CrossRef

31.

Oquendo MA, Bernanke JA (2017) Suicide risk assessment: tools and challenges. World Psychiatry 16(1):28–29CrossRef

32.

Silverman MM, Berman AL (2014) Suicide risk assessment and risk formulation part I: a focus on suicide ideation in assessing suicide risk. Suicide Life-Threat Behav 44(4):420–431CrossRef

33.

Schmitz WM, Allen MH, Feldman BN et al (2012) Preventing suicide through improved training in suicide risk assessment and care: an American Association of Suicidology Task Force report addressing serious gaps in US mental health training. Suicide Life-Threat Behav 42(3):292–304CrossRef

34.

van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, Landwehrmeyer GB (2014) Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2013-3073 CrossRefPubMed

35.

van Heeringen K, Mann JJ (2014) The neurobiology of suicide. The Lancet Psychiatry 1(1):63–72CrossRef

36.

Dogan I, Eickhoff SB, Schulz JB et al (2013) Consistent neurodegeneration and its association with clinical progression in Huntington’s disease: a coordinate-based meta-analysis. Neuro-Degener Dis 12(1):23–35. https://doi.org/10.1159/000339528 CrossRef

37.

Madsen T, Erlangsen A, Nordentoft M (2017) Risk estimates and risk factors related to psychiatric inpatient suicide—an overview. Int J Environ Res Pub Health 14(3):253CrossRef

38.

Rossetti MC, Tosone A, Stratta P et al (2017) Different roles of resilience in depressive patients with history of suicide attempt and no history of suicide attempt. Revista Brasileira de Psiquiatria 39(3):216–219CrossRef

Title: Risk factors of suicidal ideation in Huntington’s disease: literature review and data from Enroll-HD
Authors: Philipp Honrath
Imis Dogan
Olga Wudarczyk
Katharina S. Görlich
Mikhail Votinov
Cornelius J. Werner
Beate Schumann
Rena T. Overbeck
Jörg B. Schulz
Bernhard G. Landwehrmeyer
Raquel E. Gur
Ute Habel
Kathrin Reetz
the Enroll-HD investigators
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 11/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-9013-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Risk factors of suicidal ideation in Huntington’s disease: literature review and data from Enroll-HD

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2018

Significance of CSF NfL and tau in ALS

Quality of life in a German cohort of Parkinson’s patients assessed with three different measures

Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis

Vertigo and impaired pursuit eye movements in a small medial superior temporal infarction

Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations

Platelet-derived extracellular vesicles in Huntington’s disease